Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
about
Disease-modifying treatments for multiple sclerosis - a review of approved medicationsRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis"Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patientsEffects of mannose-binding lectin on pulmonary gene expression and innate immune inflammatory response to ozone.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.
P2860
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapy-related acute leukaemi ...... he risk and can it be limited?
@en
type
label
Therapy-related acute leukaemi ...... he risk and can it be limited?
@en
prefLabel
Therapy-related acute leukaemi ...... he risk and can it be limited?
@en
P2860
P356
P1476
Therapy-related acute leukaemi ...... he risk and can it be limited?
@en
P2093
Mike Boggild
Richard Ellis
P2860
P304
P356
10.1177/1352458514541508
P50
P577
2014-07-10T00:00:00Z